Multiple Sclerosis Trial, Recruiting NCT06201026 Sponsor: Centre Hospitalier Universitaire de Saint Etienne Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06201026
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with relapsing-remitting multiple sclerosis (a type of MS where symptoms come and go), confirmed using standard diagnostic guidelines
  • People diagnosed with MS less than 2 years ago, or whose first MS symptoms appeared less than 5 years ago — or people diagnosed more than 2 years ago whose first symptoms still appeared less than 5 years ago
  • People experiencing a high level of fatigue, measured by a standard fatigue questionnaire (FSS score above 4)
  • People with a disability level below a certain threshold on a standard MS disability scale (EDSS score below 4)
  • People with adequate muscle strength in all leg muscles, as assessed by a standard muscle strength test (MRC score of 4 or above)
  • People who are able to walk for 10 minutes without stopping (based on self-reporting)
  • People who own a mobile phone with internet access
  • People covered by a social security or health insurance scheme
  • People who have freely given written consent after being fully informed about the trial's purpose, process, and potential risks

Who may not be able to join:

  • People with significant muscle stiffness (spasticity) or severe balance and coordination problems (cerebellar ataxia) in either leg
  • People with limited or abnormal range of movement in their toes or ankles
  • People with a musculoskeletal injury that affects their ability to pedal
  • People who have had an MS relapse (a flare-up of symptoms) in the 90 days before the study
  • People who have recently changed any medication that could affect fatigue levels, including treatments for nerve pain, anti-epileptic drugs, or fatigue-related stimulant medications (such as modafinil, amantadine, or fampridine)
  • People with other health conditions that could put their safety at risk during the study
  • People currently taking part in another medical intervention study, or who have done so in the 30 days before this trial
  • People who are pregnant or breastfeeding
  • People who are unable to understand the purpose of the study or the conditions under which it will be conducted, or who are unable to give informed consent
  • People who are under legal guardianship or have had their personal freedoms restricted

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jean-Philippe CAMDESSANCHE, PHD, CHU DE SAINT-ETIENNE

Phone: (4)77120559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Registry
ClinicalTrials.gov
Start date
12 September 2023
Est. completion
1 July 2025

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Fatigue Severity Scale (FSS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov